Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tdap-IPV vaccine antigens are a combination of immunogenic substances derived from Clostridium tetani, Corynebacterium diphtheriae, Bordetella pertussis, and Poliovirus types 1, 2, and 3 [1]. The tetanus and diphtheria components are toxoids—chemically inactivated toxins that stimulate the production of neutralizing antibodies to prevent the systemic effects of bacterial infection [2]. The acellular pertussis component consists of purified proteins, such as pertussis toxin and filamentous hemagglutinin, which provide protection against whooping cough while minimizing the adverse reactions associated with older whole-cell formulations [3]. The inactivated poliovirus (IPV) component includes killed viruses of three distinct serotypes to induce protective immunity against paralytic poliomyelitis [4]. These antigens are typically formulated with aluminum-based adjuvants to enhance the host's immune response and ensure long-lasting memory [2]. Tdap-IPV is primarily utilized as a booster dose in adolescents and adults to maintain immunity against these four pathogens, which can cause severe respiratory distress, neurological damage, or muscle spasms [1, 3].
Induction of active immunity through the presentation of inactivated toxins and viral/bacterial proteins to the host immune system, resulting in the production of specific neutralizing antibodies and memory B and T cells [2, 3].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tetanus toxoid, reduced Diphtheria toxoid, acellular Pertussis, and Inactivated Poliovirus vaccine antigens (Tdap-IPV) (Tdap-IPV).